$3.61 Billion is the total value of BB BIOTECH AG's 27 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 3.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Sell | Celgene Corp | $464,334,000 | +10.0% | 3,184,298 | -2.0% | 12.85% | -0.3% |
| INCY | Buy | Incyte Corp. | $428,240,000 | -3.2% | 3,668,322 | +4.4% | 11.86% | -12.4% |
| IONS | Buy | Ionis Pharmaceuticals Inc. | $398,600,000 | +6.5% | 7,861,934 | +6.9% | 11.03% | -3.5% |
| GILD | Gilead Sciences Inc. | $224,798,000 | +14.5% | 2,774,596 | 0.0% | 6.22% | +3.7% | |
| VRTX | Vertex Pharmaceuticals Inc. | $224,327,000 | +18.0% | 1,475,445 | 0.0% | 6.21% | +6.8% | |
| NBIX | Buy | Neurocrine Biosciences Inc. | $212,198,000 | +33.8% | 3,462,753 | +0.5% | 5.87% | +21.2% |
| RDUS | Buy | Radius Health Inc. | $211,979,000 | -7.0% | 5,498,799 | +9.1% | 5.87% | -15.8% |
| ALXN | Alexion Pharmaceuticals Inc. | $190,013,000 | +15.3% | 1,354,428 | 0.0% | 5.26% | +4.4% | |
| AGIO | Sell | Agios Pharmaceuticals Inc. | $183,562,000 | +24.3% | 2,749,998 | -4.2% | 5.08% | +12.6% |
| HALO | Buy | Halozyme Therapeutics Inc. | $149,835,000 | +41.4% | 8,626,051 | +4.4% | 4.15% | +28.1% |
| ALNY | Sell | Alnylam Pharmaceuticals Inc. | $130,571,000 | +34.0% | 1,111,338 | -9.0% | 3.61% | +21.4% |
| TSRO | Buy | Tesaro Inc. | $128,609,000 | +4.7% | 996,193 | +13.5% | 3.56% | -5.1% |
| ESPR | Buy | Esperion Therapeutics Inc. | $105,150,000 | +50.1% | 2,097,964 | +38.6% | 2.91% | +36.0% |
| JUNO | Sell | Juno Therapeutics Inc. | $92,187,000 | +41.2% | 2,055,000 | -5.9% | 2.55% | +27.9% |
| REGN | Buy | Regeneron Pharmaceuticals Inc. | $91,660,000 | +3.7% | 205,000 | +13.9% | 2.54% | -6.1% |
| SAGE | Buy | Sage Therapeutics Inc. | $68,059,000 | -5.8% | 1,092,439 | +20.4% | 1.88% | -14.7% |
| MYOV | Buy | Myovant Sciences Ltd. | $53,803,000 | +38.6% | 3,477,882 | +4.8% | 1.49% | +25.5% |
| MGNX | Buy | MacroGenics Inc. | $44,360,000 | +7.8% | 2,400,412 | +2.1% | 1.23% | -2.4% |
| AVXS | AveXis, Inc. | $38,963,000 | +17.7% | 402,800 | 0.0% | 1.08% | +6.6% | |
| ITCI | Buy | Intra-Cellular Therapies Inc. | $34,716,000 | +30.0% | 2,200,000 | +2.3% | 0.96% | +17.8% |
| FPRX | Five Prime Therapeutics Inc. | $31,808,000 | +35.9% | 777,500 | 0.0% | 0.88% | +23.0% | |
| ICPT | Buy | Intercept Pharmaceuticals Inc. | $28,191,000 | -8.9% | 485,719 | +89.9% | 0.78% | -17.5% |
| ALDR | Buy | Alder Biopharmaceuticals Inc. | $27,759,000 | +24.9% | 2,266,008 | +16.7% | 0.77% | +13.1% |
| PRTA | Prothena Corp. PLC | $22,670,000 | +19.7% | 350,000 | 0.0% | 0.63% | +8.5% | |
| CDTX | Buy | Cidara Therapeutics Inc. | $10,816,000 | +30.8% | 1,335,272 | +21.1% | 0.30% | +18.2% |
| NVAX | Novavax Inc. | $9,496,000 | -0.9% | 8,330,000 | 0.0% | 0.26% | -10.2% | |
| ACHN | Achillion Pharmaceuticals Inc. | $5,744,000 | -2.2% | 1,279,340 | 0.0% | 0.16% | -11.2% | |
| KITE | Exit | Kite Pharma Inc. | $0 | – | -640,000 | -100.0% | -2.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N V #1
- Biotech Invest N V #2
- Biotech Target N V #3
- Biotech Growth N V #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.